| 医药行业科技成果产业化的风险控制 |
| |
| 引用本文： | 詹振鹏,曾秋琼,唐长江,罗万象.医药行业科技成果产业化的风险控制[J].国际医药卫生导报,2005,15(23):73-75. |
| |
| 作者姓名： | 詹振鹏 曾秋琼 唐长江 罗万象 |
| |
| 作者单位： | 中国药科大学国际医药商学院，中国药科大学国际医药商学院 |
| |
| 摘 要： | 医药行业科技成果产业化与其他行业科技成果转化相比具有更高的风险，转化能力也是最低的，因此，对其从事前、事中、事后三方面加强风险控制具有重要的观实意义。
|
| 关 键 词： | 医药行业 科技成果产品业化风险控制 |
Clinical analysis of Dahuang Zhechong Capsule combined with Ruhesanjie Tablet in 265 cases of cyclomastopathy |
| |
| Abstract: | Objeotlvs To study the treatment methods of cyelomastopathy.Methods The therapeutic effects of Dahuang Zhechong Capsule combined with Ruhesanjie tablet in 265 cases of cyclomastopathy were retrospectively analyzed.Results 23 of all the eases were cured or improved and the effective rate was 95.47%.Conclusions Dahuang Zhechong Capsule combined with Ruhesanjie tablet were a good method in the treatment of cyclomastopathy. |
| |
| Keywords: | Hyperplasia of mammary glandsDahuang Zheehong CapsuleRuhesanjie tablet |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
